Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B).
暂无分享,去创建一个
D. Ferry | S. Siena | J. Taieb | F. Pietrantonio | A. Sobrero | G. Lledo | R. Bordonaro | S. Bauer | E. Dochy | S. Brette | P. Garreau-Laporte